The mevalonate pathway is an attractive target to override multidrug resistance (MDR) and restore immunogenic cell death (ICD) in tumor cells. Recent data indicate that aminobisphosphonates are better tools than statins to manipulate the Mev pathway since they have synergistic effects on tumor cells and host immunity.
Inhibition of the mevalonate pathway to override chemoresistance and promote immunogenic cell death in cancer cells: hitting two birds with one stone.
RIGANTI, Chiara;MASSAIA, Massimo
2013-01-01
Abstract
The mevalonate pathway is an attractive target to override multidrug resistance (MDR) and restore immunogenic cell death (ICD) in tumor cells. Recent data indicate that aminobisphosphonates are better tools than statins to manipulate the Mev pathway since they have synergistic effects on tumor cells and host immunity.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Riganti, OncoImmunonology, 2013.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
403.7 kB
Formato
Adobe PDF
|
403.7 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
Riganti Open Access Oncoimmunolgy 2013.pdf
Open Access dal 31/07/2014
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
571.91 kB
Formato
Adobe PDF
|
571.91 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
